Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Firefly Neuroscience (AIFF) EBT (2016 - 2025)

Historic EBT for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to -$2.6 million.

  • Firefly Neuroscience's EBT rose 3847.05% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.2 million, marking a year-over-year decrease of 17326.8%. This contributed to the annual value of -$10.5 million for FY2024, which is 30192.16% down from last year.
  • According to the latest figures from Q3 2025, Firefly Neuroscience's EBT is -$2.6 million, which was up 3847.05% from -$1.8 million recorded in Q2 2025.
  • Firefly Neuroscience's 5-year EBT high stood at $456438.0 for Q2 2023, and its period low was -$12.9 million during Q1 2025.
  • Moreover, its 5-year median value for EBT was -$1.1 million (2022), whereas its average is -$2.0 million.
  • As far as peak fluctuations go, Firefly Neuroscience's EBT surged by 31435.58% in 2021, and later tumbled by 385117.13% in 2022.
  • Quarter analysis of 5 years shows Firefly Neuroscience's EBT stood at -$2.4 million in 2021, then surged by 57.39% to -$1.0 million in 2022, then dropped by 4.32% to -$1.1 million in 2023, then plummeted by 251.58% to -$3.8 million in 2024, then skyrocketed by 30.24% to -$2.6 million in 2025.
  • Its EBT was -$2.6 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$12.9 million in Q1 2025.